Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343642 · ClinicalTrials.gov registry record · Phase 1
Dietary Treatment of Crohn's Disease
A Phase 1 study of Crohn's Disease and Inflammatory Bowel Disease, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 2
- Study locations
NCT00343642: Completed Phase 1 study of Crohn's Disease and Inflammatory Bowel Disease, sponsored by Rush University Medical Center.
NCT00343642 is a Phase 1 study of Crohn's Disease and Inflammatory Bowel Disease that has completed, run by Rush University Medical Center. The registered enrollment target is 73 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00343642, a Phase 1 study of Crohn's Disease and Inflammatory Bowel Disease, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 2
- Study locations
Study Summary
Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.
Primary Outcome
The efficacy of the dietary treatment was assessed by looking at the number of participants who flared.
Conditions Studied
Interventions
- DRUG Active fructo-oligosaccharide
- DRUG Placebo fructo-oligosaccharide
- DIETARY_SUPPLEMENT Diet
Study Locations (2)
Georgia
- Gastroenterology Associates of Central Georgia - Macon
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
What the finished NCT00343642 record still lists
NCT00343642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 3 interventions - of which Active fructo-oligosaccharide is the first listed.
NCT00343642 reports a single indexed study location in Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT00343642 about?
NCT00343642 is a clinical study titled "Dietary Treatment of Crohn's Disease". Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.
What is the current status of trial NCT00343642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2006-09. Estimated completion is 2012-10.
What conditions does trial NCT00343642 study?
This clinical trial studies the following conditions: Crohn's Disease, Inflammatory Bowel Disease.
What interventions are being tested in trial NCT00343642?
The interventions under investigation include: Active fructo-oligosaccharide (DRUG), Placebo fructo-oligosaccharide (DRUG), Diet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00343642?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00343642 being conducted?
This trial has 2 study locations across Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00343642's enrollment target sits among peer trials
73 74th of 105 higher than 32 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Stem Cell Transplantation for Crohn's Disease
RECRUITING · Phase 1
-
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
RECRUITING · Phase 1
-
Beta-Hydroxybutyrate Feasibility Treating IBD
RECRUITING · Phase 1
-
Treatment of Moderate to Severe Refractory Crohn's Disease
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
ACTIVE NOT RECRUITING · Phase 1
-
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia